Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis.
作者信息
Loomba Rohit, Ratziu Vlad, Harrison Stephen A
机构信息
NAFLD Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, La Jolla, California.
Sorbonne Université, Institute of Cardiometabolism and Nutrition, Pitié-Salpêtrière Hospital, Paris, France.
出版信息
Gastroenterology. 2022 Mar;162(3):680-688. doi: 10.1053/j.gastro.2021.10.051. Epub 2021 Nov 23.
Abstract
摘要
相似文献
1
Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis.专家小组审查，以比较美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）关于非酒精性脂肪性肝炎药物开发及终点指标的指南
Gastroenterology. 2022 Mar;162(3):680-688. doi: 10.1053/j.gastro.2021.10.051. Epub 2021 Nov 23.
2
Nonalcoholic Steatohepatitis: Current Thinking From the Division of Hepatology and Nutrition at the Food and Drug Administration.非酒精性脂肪性肝炎：美国食品药品监督管理局肝脏病学与营养科的当前观点
Hepatology. 2021 May;73(5):2023-2027. doi: 10.1002/hep.31687.
3
Adolescents and Drug Development: Commentary on a Dawning Paradigm Shift.青少年与药物研发：对一场初现端倪的范式转变的评论
J Clin Pharmacol. 2021 Jun;61(6):740-743. doi: 10.1002/jcph.1862. Epub 2021 Apr 20.
4
Leveraging Clinical Pharmacology to Optimize Drug Development for Nonalcoholic Steatohepatitis and Cholestatic Liver Diseases: Workshop Report.利用临床药理学优化非酒精性脂肪性肝炎和胆汁淤积性肝病的药物研发：研讨会报告
Clin Pharmacol Ther. 2021 Feb;109(2):292-294. doi: 10.1002/cpt.1978. Epub 2020 Aug 2.
5
Minors and a Dawning Paradigm Shift in "Pediatric" Drug Development.未成年人与“儿科”药物研发中初现的范式转变
J Clin Pharmacol. 2021 Jun;61(6):736-739. doi: 10.1002/jcph.1806. Epub 2021 Jan 12.
6
Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints.非酒精性脂肪性肝病的药物研发：研究中的挑战、监管途径及研究终点
Expert Opin Drug Discov. 2021 Feb;16(2):125-134. doi: 10.1080/17460441.2020.1811674. Epub 2020 Oct 22.
7
Developing Pharmacologic Treatments for Eosinophilic Esophagitis: Draft Guidance from the United States Food and Drug Administration.开发嗜酸性粒细胞性食管炎的药物治疗方法：美国食品药品监督管理局的指导草案
Gastroenterology. 2019 Aug;157(2):275-277. doi: 10.1053/j.gastro.2019.04.020. Epub 2019 Apr 22.
8
Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease.小儿非酒精性脂肪性肝病药物研发中需考虑的因素。
Gastroenterology. 2019 Dec;157(6):1448-1456.e1. doi: 10.1053/j.gastro.2019.08.048. Epub 2019 Sep 12.
9
2020 FDA Drug-drug Interaction Guidance: A Comparison Analysis and Action Plan by Pharmaceutical Industrial Scientists.2020 年 FDA 药物相互作用指导：制药工业科学家的比较分析和行动计划。
Curr Drug Metab. 2020;21(6):403-426. doi: 10.2174/1389200221666200620210522.
10
Preclinical efficacy in therapeutic area guidelines from the U.S. Food and Drug Administration and the European Medicines Agency: a cross-sectional study.美国食品和药物管理局与欧洲药品管理局治疗领域指南中的临床前疗效：一项横断面研究。
Br J Pharmacol. 2018 Nov;175(22):4229-4238. doi: 10.1111/bph.14485. Epub 2018 Oct 1.
引用本文的文献
1
Aerobic Exercise Training Leads to MASH Resolution as Defined by the MASH Resolution Index.有氧运动训练可导致根据MASH缓解指数定义的MASH缓解。
Dig Dis Sci. 2025 Sep 3. doi: 10.1007/s10620-025-09361-9.
2
A systematic review and meta-analysis of efruxifermin's efficacy in improving liver fibrosis in patients with NASH/MASH.一项关于艾弗西费明改善非酒精性脂肪性肝炎/代谢相关脂肪性肝炎患者肝纤维化疗效的系统评价和荟萃分析。
Front Pharmacol. 2025 May 30;16:1594091. doi: 10.3389/fphar.2025.1594091. eCollection 2025.
3
Role of artificial intelligence in advancing immunology.人工智能在推动免疫学发展中的作用。
Immunol Res. 2025 Apr 24;73(1):76. doi: 10.1007/s12026-025-09632-7.
4
Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment.代谢功能障碍相关脂肪性肝病：一种具有异质性代谢风险因素、机制和合并症且需要整体治疗的疾病。
Nat Rev Gastroenterol Hepatol. 2025 May;22(5):314-328. doi: 10.1038/s41575-025-01045-z. Epub 2025 Feb 17.
5
Long-term liver outcomes after metabolic surgery in compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis.代谢功能障碍相关脂肪性肝炎所致代偿期肝硬化患者代谢手术后的长期肝脏结局
Nat Med. 2025 Mar;31(3):988-995. doi: 10.1038/s41591-024-03480-y. Epub 2025 Jan 27.
6
Nidogen 2 Overexpression Promotes Hepatosteatosis and Atherosclerosis.巢蛋白2过表达促进肝脂肪变性和动脉粥样硬化。
Int J Mol Sci. 2024 Nov 28;25(23):12782. doi: 10.3390/ijms252312782.
7
Fanlian Huazhuo Formula: A promising herbal preparation for metabolic liver disease.矾连化浊方：一种用于代谢性肝病的有前景的草药制剂。
World J Gastroenterol. 2024 Dec 14;30(46):4964-4968. doi: 10.3748/wjg.v30.i46.4964.
8
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH).代谢功能障碍相关脂肪性肝炎（MASH）的治疗前景
Nat Rev Drug Discov. 2025 Mar;24(3):171-189. doi: 10.1038/s41573-024-01084-2. Epub 2024 Nov 28.
9
Efficacy and safety of electroacupuncture for metabolic dysfunction-associated fatty liver disease: a study protocol for a multicentre, randomised, sham acupuncture-controlled, patient-blinded clinical trial.电针对代谢相关脂肪性肝病的疗效和安全性：一项多中心、随机、假针刺对照、患者盲法临床试验的研究方案。
BMJ Open. 2024 Nov 14;14(11):e084768. doi: 10.1136/bmjopen-2024-084768.
10
Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists.转化肝脂肪变性疾病管理：GLP-1 受体激动剂的新兴作用。
Hepatol Commun. 2024 Oct 10;8(11). doi: 10.1097/HC9.0000000000000561. eCollection 2024 Nov 1.
本文引用的文献
1
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis.肝硬化逆转与非酒精性脂肪性肝炎患者临床结局改善相关。
Hepatology. 2022 May;75(5):1235-1246. doi: 10.1002/hep.32204. Epub 2022 Feb 7.
2
Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation.当前肝脏供体分配系统的局限性以及肝脏移植新适应症的影响。
J Hepatol. 2021 Jul;75 Suppl 1:S178-S190. doi: 10.1016/j.jhep.2021.01.007.
3
Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease.MRI-PDFF 下降 30%对预测非酒精性脂肪性肝病纤维化消退的临床效用。
Gut. 2022 May;71(5):983-990. doi: 10.1136/gutjnl-2021-324264. Epub 2021 Apr 21.
4
Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.前瞻性评估大型美国中年队列中非酒精性脂肪性肝病和脂肪性肝炎的患病率。
J Hepatol. 2021 Aug;75(2):284-291. doi: 10.1016/j.jhep.2021.02.034. Epub 2021 Mar 18.
5
The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.非酒精性脂肪性肝炎所致晚期纤维化患者的组织学和非侵入性检查与不良临床和患者报告结局的相关性。
Gastroenterology. 2021 Apr;160(5):1608-1619.e13. doi: 10.1053/j.gastro.2020.12.003. Epub 2020 Dec 8.
6
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials.肝活检评估的可靠性欠佳对随机临床试验有影响。
J Hepatol. 2020 Dec;73(6):1322-1332. doi: 10.1016/j.jhep.2020.06.025. Epub 2020 Jun 28.
7
Advances in non-invasive assessment of hepatic fibrosis.肝纤维化无创评估的进展。
Gut. 2020 Jul;69(7):1343-1352. doi: 10.1136/gutjnl-2018-317593. Epub 2020 Feb 17.
8
Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD.2012 年至 2017 年全球慢性肝病负担的变化：非酒精性脂肪性肝病的影响日益增加。
Hepatology. 2020 Nov;72(5):1605-1616. doi: 10.1002/hep.31173. Epub 2020 Oct 27.
9
Donor Small-Droplet Macrovesicular Steatosis Affects Liver Transplant Outcome in HCV-Negative Recipients.供体微小滴状大泡性脂肪变性影响 HCV 阴性受者肝移植的结局。
Can J Gastroenterol Hepatol. 2019 May 2;2019:5862985. doi: 10.1155/2019/5862985. eCollection 2019.
10
Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.在伴有或不伴有利巴韦林的情况下，索磷布韦-维帕他韦治疗失代偿期肝硬化的 HCV 感染日本患者的疗效和安全性：一项开放标签 3 期试验。
J Gastroenterol. 2019 Jan;54(1):87-95. doi: 10.1007/s00535-018-1503-x. Epub 2018 Sep 10.
Zotero 插件